Health news
Health news top Health news

   Login  |  Register    
Health News Make AMN Your Home PageDiscussion BoardsAdvanced Search ToolMedical RSS/XML News FeedHealth news
  You are here : > Health Centers > Cancer - Drug Abuse -
FDA staff say calcitonin salmon cancer risk appears plausible FDA staff say calcitonin salmon cancer risk appears plausible

FDA staff say calcitonin salmon cancer risk appears plausible

Cancer • • Drug AbuseMar 03, 2013

Staff reviewers for the U.S. Food and Drug Administration said that a potential increased risk of cancer with drugs containing calcitonin salmon appears plausible.

In briefing documents released on Friday, the reviewers said the risk raises concerns about the overall risk versus benefit of calcitonin products to treat osteoporosis in postmenopausal women.

Calcitonin products include Novartis AG’s Miacalcin injection and nasal spray and Unigene Laboratories Inc’s nasal spray. Privately held Upsher Smith Laboratories Inc distributes Unigene’s product in the United States. Generic calcitonin products are also available.

Calcitonin salmon is a man-made version of the hormone calcitonin that is found in salmon.

The reviewers said significant questions remain about calcitonin salmon’s effectiveness in reducing fractures in the treatment of postmenopausal osteoporosis.

An advisory panel to the FDA is scheduled to discuss the products on March 5 and will make a recommendation to the agency on whether to allow the continued marketing of these products for that use.

Last July European regulators recommended that long-term use of calcitonin be curtailed after a review found evidence of a small increased risk of cancer with long-term use of the drugs.

They recommended that they should only be authorized for short-term use in Paget’s disease, a bone disorder; for acute bone loss due to sudden immobilization; and for excess calcium in the blood caused by cancer. They ruled that the benefits of calcitonin-containing medicines did not outweigh their risks in the treatment of osteoporosis and that they should no longer be used for this condition.

Unigene officials declined to comment on the FDA staff review as they do not distribute a calcitonin product in the United States. Upsher Smith officials were not immediately available for comment. Novartis said in a statement that it “places the highest priority on patient safety and the appropriate use of its medicines and is looking forward to the opportunity to engage in the discussion at the upcoming meeting.”

Unigene shares were down 20.65 percent at $0.12 on the pink sheets. Novartis shares were up 1 percent.


By Toni Clarke|

Provided by ArmMed Media

FDA staff say calcitonin salmon cancer risk appears plausible Bookmark this! FDA staff say calcitonin salmon cancer risk appears plausible


We are pleased to let readers post comments about an article. Please increase the credibility of your post by including your full name and email.

All comments are reviewed by our editors before they are posted on the site. Just keep it clean, kids. Commenting is not available in this weblog entry.

   [advanced search]   
What health info have you recently searched for online?
Disease or condition
Exercise or fitness
Diet, nutrition or vitamins
None of the above

Get free support - Headache Causes, Symptoms, Diagnosis, and Treatment on

Health Centers


Health news

Health Encyclopedia

Diseases & Conditions

Drugs & Medications

Health Tools

Health Tools

   Health newsletter


   Medical Links

   RSS/XML News Feed


Add to Yahoo RSS News Feed

Google Reader


This website is accredited by Health On the Net Foundation. Click to verify. We comply with the HONcode standard for trustworthy health information:
Verify here.